Tuesday, November 17, 2026
Biotech

Novo Nordisk Tests Wegovy for Younger Children

Novo Nordisk says its weight loss drug Wegovy helped young children lower their body weight in a new study.

Childhood obesity is a growing challenge for families across the country. Doctors often have few tools to help younger patients manage severe weight issues. Novo Nordisk aims to change that reality with its popular weight loss drug.

The drug maker shared new trial results for Wegovy. Children in the study had lower body mass index scores after taking the shots. Obesity rates also dropped among the kids who took the medicine. Wegovy already has approval for teenagers, but doctors have no approved weight loss drugs for children under 12.

The new data opens a path for the company to ask health regulators for approval. If approved, the drug could reach millions of younger kids who need medical help to stay healthy. Novo Nordisk continues to lead the growing market for weight loss treatments.

This trial shows that demand for these treatments is expanding beyond adults. Watch for regulatory updates in the coming months. These results could secure the company's lead in a rapidly growing health sector.

Source: CNBC

#Biotech#Novo Nordisk#Wegovy#Healthcare#Investing

More from Biotech